

Situational Report in the ASEAN Region

—— ASEAN BioDiaspora Virtual Center (ABVC)



ASSOCIATION
OF SOUTHEAST
ASIAN NATIONS



ASEAN
BIODIASPORA
VIRTUAL CENTER



MINISTRY OF HEALTH
REPUBLIC OF INDONESIA

GLOBAL PARTNERS



In partnership with
Canada



**World Health
Organization**



Korea Disease Control and
Prevention Agency



Table of Contents

COVID-19	1
Highlights and Situation Overview	1
Global Update	1
Research Update	1
COVID-19 Cases and Deaths Table	4
COVID-19 Cases in ASEAN Region Table	4
Epi curve Among ASEAN Countries	5
ASEAN Weekly New Cases and New Deaths	6
Vaccination Status in ASEAN	7
Mpox	8
Map of Mpox Cases Globally	8
Mpox Daily Trend Globally	9
Highlights and Situation Overview	10
Mpox Cases in ASEAN Region Table	10
Mpox Cases in Asia-Pacific Region Table	10
Top 5 Countries with Most Mpox Cases Globally	10
Mpox Cases per Region	11
References	12



COVID-19: Highlights and Situation Overview

Global Update

- **Worldwide**, over 688 million cases and over 6 million deaths have been attributed to COVID-19.
- The **World Health Organization (WHO)** reported in its latest weekly update that global COVID-19 cases declined by 14% and deaths by 17% over the past 4 weeks compared to the previous 4 weeks.¹ However, cases rose sharply in Southeast Asia, with a more modest rise in the Western Pacific.¹ Hot spots in the WHO's Southeast Asia region, include India, Indonesia, Thailand, Myanmar, and Maldives.¹ Meanwhile, the rising activity in the Western Pacific is led by increases in Vietnam, Mongolia, Laos, Australia, Japan, and South Korea.¹ The WHO's Eastern Mediterranean region had been experiencing a spike in activity over the past several weeks, but activity over the past 4 weeks has stabilized.¹ The WHO said subvariant dominance varies by region, with XBB.1.16 dominant in Southeast Asia and XBB.1.5 dominant in the Western Pacific.¹ Globally, XBB.1.5 continues to dominate, but its proportions are steadily dropping.¹ Other subvariants continue to rise, including XBB.1.16, which has now been reported in 46 countries and has increased from 4% to 8.6% of sequences over the past 4 weeks.¹ Other variants under monitoring showing increasing trends include XBB, XBB.1.9.1, and XBB.1.9.2.¹ [\[Full report\]](#)
- The **European Centre for Disease Prevention and Control (ECDC)** said country trends over the past several weeks continue to decline or are stable.² Recent transmission and severe disease rise in Bulgaria, Croatia, Finland, and France appear to be at or past their peaks.² Spain's primary care surveillance hints at increased community transmission, which the ECDC said isn't reflected in the country's reported case rates.² Meanwhile, sequencing from a limited number of countries suggests that XBB.1.5 makes up 62.7% of the samples.² [\[Full report\]](#)
- **US CDC:** In the United States, health officials are adjusting to a shift in Centers for Disease Control and Prevention (CDC) data reporting, which was announced ahead of the end of the national public health emergency.³ The new metrics focus less on case rates and lean more heavily on hospital and death data.³ Hospitalizations for COVID-19 continue to slow, declining 6.5% last week.³ Deaths also reflect a slow and steady decline, dropping 5.3% over the past week.³ Meanwhile, the CDC is shifting to every-other-week reporting for variant proportion projections.⁴ This week's report shows that, over the past 2 weeks, XBB.1.5 makes up 64% of samples, down from 76.3% from the previous 2 weeks.⁴ Levels of XBB.1.16 rose from 6.6% to 14.3% over the same period, with levels of XBB.1.9.1 rising from 6.5% to 9.2%.⁴ Other subvariants reflexing increased proportions include XBB.1.9.2 and XBB.2.3.⁴ [\[Full report\]](#) [3](#), [4](#)

Research Update (Published and peer-reviewed studies)

- This multicenter cross-sectional study, ***Prevalence of Urinary Tract Infection, Bacteremia, and Meningitis Among Febrile Infants Aged 8 to 60 Days With SARS-CoV-2***, described the prevalence of UTI, bacteremia, and bacterial meningitis among febrile infants aged 8 to 60 days with SARS-CoV-2 vs without SARS-CoV-2.⁵ Participants included full-term, previously healthy, well-appearing infants aged 8 to 60 days seen in 106 hospitals in the US and Canada and who had no bronchiolitis but with a temperature of at least 38 °C and who underwent SARS-CoV-2 testing in the emergency department or hospital between November 1, 2020, and October 31, 2022.⁵ Outcomes were ascertained by medical record review and included the prevalence of UTI, bacteremia without meningitis, and bacterial meningitis.⁵ The proportion of infants who were SARS-CoV-2 positive vs negative was calculated for each infection type, and stratified by age group



and normal vs abnormal inflammatory markers (IMs).⁵ Among 14,402 febrile infants with SARS-CoV-2 testing, 8,413 (58.4%) were aged 29 to 60 days; 8143 (56.5%) were male; and 3753 (26.1%) tested positive.⁵ Compared with infants who tested negative, a lower proportion of infants who tested positive for SARS-CoV-2 had UTI (0.8%[95%CI, 0.5%-1.1%]) vs 7.6% [95%CI, 7.1%-8.1%]), bacteremia without meningitis (0.2%[95%CI, 0.1%-0.3%] vs 2.1%[95%CI, 1.8%-2.4%]), and bacterial meningitis (<0.1%[95%CI, 0%-0.2%] vs 0.5% [95%CI, 0.4%-0.6%]).⁵ Among infants aged 29 to 60 days who tested positive for SARS-CoV-2, 0.4% (95%CI, 0.2%-0.7%) had UTI, less than 0.1% (95%CI, 0%-0.2%) had bacteremia, and less than 0.1% (95%CI, 0%-0.1%) had meningitis. Among SARS-CoV-2-positive infants, a lower proportion of those with normal IMs had bacteremia and/or bacterial meningitis compared with those with abnormal IMs (<0.1%[0%-0.2%] vs 1.8%[0.6%-3.1%]).⁵ The prevalence of UTI, bacteremia, and bacterial meningitis was lower for febrile infants who tested positive for SARS-CoV-2, particularly infants aged 29 to 60 days and those with normal IMs.⁵ These findings may help inform the management of certain febrile infants who test positive for SARS-CoV-2.⁵ [\[Full text\]](#)

- This cohort study among children with cancer and COVID-19, **Clinical Features and Risk Factors Associated with Multisystem Inflammatory Syndrome in Children with Cancer and COVID-19**, evaluated factors associated with multisystem inflammatory syndrome in children (MIS-C) and described the clinical course of COVID-19 in the setting of MIS-C.⁶ This study utilized a registry representing more than 100 US pediatric oncology sites. All included patients were registered between April 1, 2020, and May 18, 2022.⁶ Sites submitted deidentified data surrounding socio-demographics, cancer diagnosis and treatment, and COVID-19 course (symptoms, maximum support required, outcome).⁶ Patients with MIS-C (n = 24) were compared with matched controls (n = 96).⁶ Children (<21 years) with cancer who developed COVID-19 while receiving cancer treatment or within 1 year of completing treatment were characterized based on their development of MIS-C.⁶ Among 2,035 children with cancer and COVID-19, 24 (1.2%) developed MIS-C. COVID-19 occurred at a median (IQR) age of 12.5 (5.5-17.1) years in those with MIS-C and 11 (6-16) years among matched controls (P = .86).⁶ The majority of children with MIS-C had hematologic cancer (83.3% [n = 20]), were publicly insured (66.7% [n = 16]), and were Hispanic (54.2% [n = 13]).⁶ Half (n = 12) had 1 or more noncancer comorbidity. Those with comorbidities were more likely to develop MIS-C than those without (odds ratio [OR], 2.5 [95% CI, 1.1-5.7]).⁶ Among children with MIS-C, 100% (n = 24) were admitted to the hospital and 54.2% (n = 13) to the intensive care unit (ICU), while COVID-19 contributed to the death of 20.1% (n = 5); cancer therapy was changed in 62.5% (n = 15).⁶ Compared with matched controls, those with MIS-C had higher odds of symptoms classified as systemic (OR, 4.7 [95% CI, 1.4-15.8]) or gastrointestinal (OR, 5.0 [95% CI, 1.7-14.6]) along with higher odds of hospitalization (OR, 42.9 [95% CI, 7.1-258]), ICU admission (OR, 11.4 [95% CI, 3.6-36.4]), and changes to cancer therapy (OR, 24.9 [95% CI, 6.5-94.8]).⁶ Among children with cancer and COVID-19, those with MIS-C had a more severe clinical course than those without MIS-C.⁶ The risk of MIS-C and its severity are important to consider as clinicians monitor patients with COVID-19.⁶ [\[Full text\]](#)
- The long-term consequences of COVID-19 on mental health are a critical issue given the number of people infected with SARS-CoV-2 worldwide since the beginning of the pandemic.⁷ This cohort study, **Comparison of Depression and Anxiety Following Self-reported COVID-19-Like Symptoms vs SARS-CoV-2 Seropositivity in France** investigated the association between self-reported COVID-19-like symptoms or SARS-CoV-2 seropositivity and subsequent depression or anxiety.⁷ The study used data from a large, randomly selected, national population-based cohort from France, the EpiCoV (Epidémiologie et Conditions de Vie) study.⁷ Of 85,074 individuals 15 years or older who completed the questionnaires at the 3 collection times, 28,568 were excluded because they did not return a blood sample for serologic testing, 1,994 because of missing data on outcomes or exposures, and 9,252 to respect the temporal sequence (exposure must



precede the outcome).⁷ Propensity scores based on various socioeconomic, lifestyle, and health variables were computed to match participants who experienced COVID-19-like symptoms between February and November 2020 or showed SARS-CoV-2 seropositivity in November 2020.⁷ Among the 45,260 included participants (mean [SD] age, 51.1 [18.9] years; 52.4% women; 8.0% with depression and 5.3% with anxiety in July 2021), COVID-19-like symptoms were associated with subsequent depression (adjusted odds ratio, 1.70; 95% CI, 1.45-1.99) and anxiety (adjusted OR, 1.57; 95% CI, 1.29-1.92), whereas SARS-CoV-2 seropositivity was not.⁷ Furthermore, COVID-19-like symptoms, but not anosmia or dysgeusia alone, were associated with subsequent depression and anxiety in both the seropositive and seronegative subgroups.⁷ Thus, SARS-CoV-2 infection was not found as a risk factor for subsequent depression or anxiety.⁷ Moreover, self-reported COVID-19-like symptoms were associated with depression and anxiety assessed at least 8 months later in both seropositive and seronegative subgroups, suggesting that factors other than SARS-CoV-2 infection are implied in this association.⁷

[\[Full text\]](#)



Cases and Deaths as of 15 May 2023

- As of 15 May 2023 (1PM, GMT+7), worldwide, there were **688,305,116** confirmed cases, including **6,874,374** deaths. Globally, Case Fatality Rate (CFR) was **1.0%**.
- 35,994,816 confirmed cases** of COVID-19 have been reported in the **ASEAN Region**.
- The Case Fatality Rate in the **ASEAN** Region is range between **0.1 to 3.1%**

COVID-19 cases in ASEAN region

REGION	COUNTRY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASEAN REGION	Brunei Darussalam	10 Mar 20	11-May-23	292,644	-	225	-	64,053	450,404	445,929	338,987	99.3
	Cambodia	27 Jan 20	09-May-23	138,736	-	3,056	-	841	15,244,858	14,609,937	10,433,215	87.1
	Indonesia	02 Mar 20	15-May-23	6,797,583	247	161,611	2	2,490	203,657,535	172,693,321	67,952,274	62.7
	Lao PDR	24 Mar 20	15-May-23	218,101	3	758	-	3,041	5,888,649	5,222,417		69.4
	Malaysia	25 Jan 20	06-May-23	5,079,436	-	37,028	-	15,788	28,125,245	27,536,657	17,056,957	81.1
	Myanmar	23 Mar 20	14-May-23	637,249	-	19,494	-	1,173	34,777,314	27,545,329	2,227,351	50.8
	Philippines	30 Jan 20	14-May-23	4,115,202	-	66,453	-	3,771	78,369,243	73,937,435	21,341,197	64.0
	Singapore	23 Jan 20	07-May-23	2,391,248	-	1,727	-	39,049	5,161,990	5,120,768	4,440,289	90.8
	Thailand	13 Jan 20	08-May-23	4,734,000	-	33,967	-	6,791	57,005,497	53,486,086	32,143,431	74.6
	Vietnam	23 Jan 20	14-May-23	11,590,617	-	43,201	-	11,950	90,450,881	85,848,363	57,452,750	87.4
ASEAN COUNTRIES				35,994,816	250	367,520	2	148,946	519,131,616	466,446,242	213,386,451	

*There have been no tests reported in the last 14 days in the **ASEAN** Region.


REGION	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS
ASIA	195,362,533	8,856	1,205,876	16
AFRICA	12,821,863	494	258,750	
AMERICAS	194,983,393		2,985,672	
EUROPE	249,142,511		2,056,556	-
TOTAL	652,310,300	9,350	6,506,854	16

**Data References: [Andra Farm](#), [Worldometer](#), [DOH Philippines](#), and the [WHO](#)



COVID-19 Epi curve among ASEAN Countries:

From January 1, 2022 to May 15, 2023




Cumulative cases of COVID-19 in the ASEAN Region as of May 15, 2023 (Report generated by ASEAN Biodiaspora Virtual Center)

*Data from Bluedot Insights, cases may differ from how data is reported in countries and other authorities. Data may be subject to retrospective correction by national authorities.



ASEAN Weekly COVID-19 New Cases and New Deaths


From January 1, 2022 to May 14, 2023





ASEAN COVID-19 Vaccination Status

as of 09 March 2023




*Last update in COVID-19 vaccination status in ASEAN was on March 9, 2023.





Mpox Cases Reported Globally


as of May 12, 2023





Mpox Daily Trend Globally

as of May 12, 2023





Mpox: Highlights and Situation Overview

- As of 12 May 2023 (1PM, GMT+7), worldwide, there were **87,412** confirmed cases, including **140** deaths. Globally, Case Fatality Rate (CFR) was **0.16%**.
- 58 confirmed cases** in the ASEAN region, with CFR of **0%**.
- 87,354 confirmed cases** of Mpox have been reported in other **5 regions** (other than ASEAN region):

Mpox cases in ASEAN region

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Indonesia	1	-	-	0.00%
Philippines	4	-	-	0.00%
Singapore	25	-	-	0.00%
Thailand	26	5	-	0.00%
Vietnam	2	-	-	0.00%
ASEAN Total	58	5	-	0.00%

Mpox cases in Asia-Pacific region

Country/Territory	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Australia	145	-	-	0.00%
India	22	-	1	4.55%
Japan	127	-	-	0.00%
New Caledonia	1	-	-	0.00%
New Zealand	41	-	-	0.00%
People's Republic of China*	87	16	-	0.00%
Republic of Korea	68	8	-	0.00%
Sri Lanka	2	-	-	0.00%
Asia-Pacific Total	493	24	1	0.20%

*People's Republic of China – including Hong Kong (SAR), Macao (SAR), and Taiwan (Province of China)

Top 5 countries with the most mpox cases globally

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
United States of America	30,154	-	42	0.14%
Brazil	10,920	-	16	0.15%
Spain	7,551	-	3	0.04%
France	4,146	-	-	0.00%
Colombia	4,090	-	-	0.00%



Mpox cases per region

REGION	TOTAL CONFIRMED CASES SINCE JANUARY 1, 2022	NEW CASES SINCE THE PREVIOUS REPORT	TOTAL DEATHS	CASE FATALITY RATE
AFRICA	1,626	7	19	1.17%
AMERICAS	59,294	1	114	0.19%
ASEAN	58	5	-	0.00%
ASIA PACIFIC	493	36	1	0.20%
EUROPE	25,616	-	6	0.02%
MIDDLE EAST	325	-	-	0.00%
TOTAL	87,412	49	140	0.16%



References

1. "Weekly Epidemiological Update on COVID-19 - 11 May 2023." *World Health Organization*, 11 May 2023, www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2023.
2. "Weekly COVID-19 Country Overview." *European Centre for Disease Prevention and Control*, 11 May 2023, www.ecdc.europa.eu/en/covid-19/country-overviews.
3. "National Emergency Department Visits for Covid-19, Influenza, and Respiratory Syncytial Virus." *Centers for Disease Control and Prevention*, 6 May 2023, www.cdc.gov/ncird/surveillance/respiratory-illnesses/index.html.
4. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2023, May 15. <https://covid.cdc.gov/covid-data-tracker>
5. Aronson, Paul L., et al. "Prevalence of Urinary Tract Infection, Bacteremia, and Meningitis among Febrile Infants Aged 8 to 60 Days with SARS-COV-2." *JAMA Network Open*, vol. 6, no. 5, 12 May 2023, <https://doi.org/10.1001/jamanetworkopen.2023.13354>.
6. Martin, Samantha D., et al. "Clinical Features and Risk Factors Associated with Multisystem Inflammatory Syndrome in Children with Cancer and Covid-19." *JAMA Oncology*, 11 May 2023, <https://doi.org/10.1001/jamaoncol.2023.0525>.
7. Rouquette, Alexandra, et al. "Comparison of Depression and Anxiety Following Self-Reported COVID-19-like Symptoms vs SARS-COV-2 Seropositivity in France." *JAMA Network Open*, vol. 6, no. 5, 11 May 2023, <https://doi.org/10.1001/jamanetworkopen.2023.12892>.



Report generated by

ASEAN Biodiversity Virtual Center (ABVC)
in collaboration with **Bluedot Inc.**

Email: support@biodiaspora.org

Facebook: <https://facebook.com/ASEANBiodiaspora>

Instagram: <https://instagram.com/ASEANBiodiaspora>



In partnership with
Canada